Target Product Profiles for Drug-Drug and Drug-Device MPT Products
|
|
- Stella Gibson
- 5 years ago
- Views:
Transcription
1 Target Product Profiles for Drug-Drug and Drug-Device MPT Products Joe Romano, Ph.D. NWJ Group, LLC Microbicide Trials Network January 10, 2012
2 Genesis of the Drug-Drug/Drug Device Working Group May 5, 2011 Think Tank USAID, CAMI, AVAC Think Tank Description of a TPP: How a proposed candidate product addresses critical attributes Outline framework for development via target specification range Why a TPP? To define attributes/parameters for MPT products with highest potential public health impact (i.e., prioritization) To Guide donor investment and sponsor development strategies Two working groups formed Drug-Drug/Drug Device Vaccines
3 Can a Single TPP for Drug-Drug or Drug-Device MPT Products Be Built? Non- HC Anti- Microbial HC Pro-Biotic Anti- Viral Barrier Anti- Fungal HIV Chlamydia BV HSV Pregnancy Gonorrhea Candida HPV Syphilis Trichomonas Vaginal Film Vaginal Tablets Topical Daily Topical Peri-Coital Oral Tablet Vaginal Ring Non-IVR Device Vaginal Gel Systemic Sustained Topical Sustained Injectable Implantable Oral Daily Oral Peri- Coital
4 Working Group Approach: Address General Concepts (not specific product configurations) Build/populate TPP component tables based on general product concepts (n=5) Other Survey Input Solicit detailed expert review and comment (n= 8-14, R&D/provider/user experts) Consolidate consensus views around concepts; capture outlier positions Report Results for Comment
5 Table 1: Prioritization of Multipurpose Prevention Technology Indications Indication Description Magnitude of priority; public health impact in target populations; definition of most relevant target populations; other HIV Prevention/ Contraception HIV/STI Prevention STI Prevention/ Contraception Single product preventing HIV transmission/ pregnancy Single product preventing HIV/STI transmission Single product preventing STI transmission/ pregnancy Highest Priority: Highest potential for impact to prevent both pregnancy and HIV in low resource settings Medium Priority, determined largely by the specific STI, and relevance to HIV transmission Medium priority, determined largely by the specific STI, and consequent disease burden for women
6 Table 2: Prioritization of STI Indications for MPT Product Development Target STI in MPT Proposed Priority Rationale HSV Very High High Incidence, HIV co-factor HPV Very High High incidence, burden of disease BV High Incidence, potential enhancement of HIV infection Chlamydia Moderate Incidence, disease burden syndromic management potential Trichomonas Moderate Incidence, disease burden, syndromic management potential Gonorrhea Low Incidence, disease burden Syphilis Low Incidence, disease burden
7 Tables 1 and 2: Consensus Responses HIV/Contraception slightly higher priority than HIV/STI STI/Contraception not a priority HSV: high priority given role in HIV infection, feasibility prospects, and marketing potential worldwide HPV: moderate to high priority given oncogenic potential Seen addressable via vaccine; availability needs to be increased Possible MPT product to cover all HPV types and bridge gap to vaccine availability BV: high priority given relevance of vaginal health to HIV and other infections
8 Tables 1 and 2: Consensus Responses (continued) Chlamydia: moderate priority given high prevalence in certain settings; high disease burden potential Curable with cheap antibiotic course Age specific screening and treatment is effective Trichomoniasis: moderate priority given high disease burden, induced inflammation and enhanced HIV shedding Product feasibility challenges recognized for prevention Gonorrhea and Syphilis: low priority Prevalence and curability cited Key factors: Relevance to HIV; technical feasibility; prevalence; treatability; public health burden
9 Table 3: Routes of Administration and Dosage Forms Route of Administration Topical: Daily Dosage Form(s) Gels, tablets films, etc. Development Priority 2.1 Adherence Potential 3.0 Topical: Peri-coital Gels, tablets, films, etc Sustained Release Device Injectable Implantable Oral: Daily IVR, barrier device with drug release Single product/ Dual indication Single product/ Dual indication Single pill/ Dual Indication Oral: Peri-coital Single pill/ dual indication Scale: 1= highest priority/potential; 3= lowest priority/potential
10 Tables 3: Consensus Responses Adherence! Vaginal rings: Highest development priority/highest adherence potential Technical feasibility high; cheap; proven contraception technology Use in menses? User removal? Peri-coital products were higher priority than daily products Adherence burden too high for daily Peri-coital cheaper than daily Peri-coital must be fast acting; technical challenge Component elements for oral daily are available; technically feasible Topical products were higher priority than oral products Topical contraceptives have technical challenges
11 Tables 3: Consensus Responses (Continued) Injectable: High adherence potential (pending dosing interval) Reversibility issues Long term systemic exposure concerns Technically challenging Skilled provider? Implantable: High adherence potential Technically challenging/low feasibility More reversible than injectable Potentially low uptake in target populations; skilled provider required Other key points: No mention of HC issue and dosage form linkage Efficacy cited as relevant to dosage form preference Side effects via systemic exposure repeatedly cited Peri-coital definition ranged from +/- 30 min to +/- 24 hr
12 Were the Results Consistent? Priority Indication by Ad Hoc epolls MPT Symposium Nov, 2011 n= ~120 32% 11% 57% Contraception & HIV Contraception & STI HIV & STI ICFP Dec, 2011 n= ~300 6% 25% 66% ARHP Meeting Sept, 2011 n= ~600 40% 66% 17% 25% 43%
13 Were the Results Consistent? Priority STI Ad Hoc epolls 28% Indication MPT Symp ICFP ARHP BV Not asked 4% 19% Candida 0% 4% Not asked CT 66% 7% 13% Not asked Gonorrhea 2% 9% Not asked HPV 31% 38% 54% HSV 57% 8% 27% Syphilis 2% 23% Not asked Trichomonas 1% 1% Not asked
14 Were the Results Consistent? Priority Dosage Forms Ad Hoc epolls Dosage Form MPT Symp ICFP ARHP 28% Implant 4% 17% 41% Injection 66% 9% 22% IUD Not asked 18% Not asked Oral Pills 3% 12% 19% Sustained Release 59% 20% 25% Topicals 25% 11% 15%
15 Table 4: Product Attributes & Parameters Parameter Range Dosage Forms Topical Sustained Injectable Implantable Oral Release Shelf Life Min 24 mos 24 mos 24 mos 24 mos 24 mos Pref >36 mos >36 mos >36 mos > 36 mos >36 mos Storage Conditions Min o C/65% RH o C/65% RH 4 o C 4 o C o C/65% RH Pref >30 o C/75% RH >30 o C/75% RH >30 o C/75% RH 40 o C/75% RH o C/75% RH Schedule/ Dosing Min Daily or Pericoital Monthly 2 mos 3 mos Daily or Pericoital Regimen Pref +/-24 hr of sex Yearly 12 mos >12 mos +/- 24 hr of sex Infrastructure Needs Min Clinic w/medical support Clinic w/medical support Clinic w/medical support Clinic w/ medical support Clinic w/medical support Pref Local Healthcare Provider Local Healthcare Provider Local Healthcare Provider Clinic w/ medical support Local Healthcare Provider
16 Table 4: Product Attributes & Parameters (Continued) Parameter Range Dosage Forms Topical Sustained Injectable Implantable Oral Release Provision Min Clinic/User Clinic/User Clinic/Phys Clinic/Physician Clinic/User Source and Administration Pref Reversibility timing Local Healthcare Provider or Pharmacy/User Packaging Min Controlled disposal Local Healthcare Provider or Pharmacy/User Trained Healthcare Provider Trained Healthcare Provider Local Healthcare Provider or Pharmacy/User Min 14 days 30 days 90 days 90 days 14 days Pref Immediate <24 hours 14 days?? Feasible? 14 Days?? Feasible? <24 hours Controlled Controlled disposal disposal Pref Concealable, user disposal Concealable, user disposal With all necessary materials for administration With all necessary materials for administration??? Biodegradable? Removable? Responders raised the issue of uptake potential for specific products Concealable, user disposal
17 Table 4: Consensus Summary Generally accepting of parameters as posed All attributes considered high priority except: Reversibility timing (medium) and packaging (low)- no consensus Strong preference for 40 o C storage temp 4 o C seen as potentially not feasible Preference for 36 month shelf life Resupply issues, access to testing/monitoring, cold chain storage needs all cited as relevant Concerns re: Packaging (sterility) and storage (temperature) for injectable and implantable Dosing interval also of concern
18 Table 5: General Issues Parameter Minimally Acceptable Preferred Target Efficacy HIV 40%-70% pending product >80% type/indication Contraception Current levels w/ recommended use >current levels per contraceptive form STI 40% >80% Side Effects Contraindications, warnings, use w/ pregnancy, etc OTC with no pregnancy or major systems warnings or contraindication with other vaginal products Time to licensure 8-12 years 5 years R&D costs <$400M <$150M Yearly MPT product cost per user <$100/year <$50/year
19 Tables 5: Consensus Summary HIV Efficacy: Minimally acceptable %; Typical use- 60%; Perfect use >80% Contraception Efficacy: Current levels with recommended use Efficacy-STI: Minimally acceptable %; no comments on posed >80% preferred target Side Effect Issues: Acceptable to most women and generally no worse than comparable single use products No effects on daily activities Difficult to answer in the absence of other details (e.g., product efficacy) Continued concerns expressed regarding systemic exposure/resistance
20 Summary TPP Findings from the Drug-Drug and Drug-Device MPT Working Group Priority Indications: HIV/Contraception followed closely by HIV/HSV Other STI with contraception not a priority Dosage Forms Major determining factor is PRODUCT ADHERENCE Highest development priority: Vaginal Rings Key Attributes and Parameters: Shelf life: 36 months Storage temperature: 40 o C epolls? Other attributes are all in the context of safety, efficacy, and each other!
21 Summary Findings from the TPP Survey for Drug-Drug and Drug-Device MPT Products Efficacy Targets: HIV: 40-80% Contraception: Current levels with recommended use STI: at least 40% Side Effects: No worse than individual indication products Needs evaluation in the context of acceptability and efficacy No significant input on cost of R&D, time to market, user costs, IP Results can vary depending on who is asked
22 Conclusions of the TPP Survey Exercise Defining broadly applicable attributes and parameters for all drug-drug or drug-device MPT products is challenging The interplay of different attributes is complex and unique per product concept and design It is possible to create general development priorities and fundamental design targets for such MPT products Useful to funders in terms of investment prioritization Useful to developers in terms of R&D focus
23 Outstanding Issues/Questions/Challenges Regarding Drug-Drug or Drug-Device MPT Products Complete collection of input (Regional studies?) Evaluate specific product concepts against key attributes and parameters of the (evolving) TPP Foster/manage collaborative funding and development of high priority/high impact products to achieve maximum efficiency Pursue the developed world potential of MPT products Build and deliver high impact MPT products to the primary target populations
24 Discussion & Questions Thank You
Target Product Profiles for Drug-Drug and Drug-Device MPT Products. Joe Romano, Ph.D. NWJ Group, LLC Microbicide Trials Network
Target Product Profiles for Drug-Drug and Drug-Device MPT Products Joe Romano, Ph.D. NWJ Group, LLC Microbicide Trials Network November 3, 2011 Genesis of the Drug-Drug/Drug Device Working Group May 5,
More informationMultipurpose Prevention Technologies (MPTs) for Sexual & Reproductive Health
Multipurpose Prevention Technologies (MPTs) for Sexual & Reproductive Health Session Objectives This session is designed to help you: Define multipurpose prevention technologies (MPTs) Describe 3 benefits
More informationWhat do women want? EMERGING TECHNOLOGIES IN REPRODUCTIVE HEALTH PANEL DISCUSSION
What do women want? EMERGING TECHNOLOGIES IN REPRODUCTIVE HEALTH PANEL DISCUSSION PANELISTS: SAUMYA RAMARAO SABRINA JOHNSON NOMITA CHANDHIOK BEATRICE MUTALI POPULATION COUNCIL WOMANCARE GLOBAL INDIAN COUNCIL
More informationMULTIPURPOSE PREVENTION TECHNOLOGIES (MPTS) FOR SEXUAL AND REPRODUCTIVE HEALTH
MULTIPURPOSE PREVENTION TECHNOLOGIES (MPTS) FOR SEXUAL AND REPRODUCTIVE HEALTH Bethany Young Holt, PhD MPH Executive Director, CAMI Reproductive Health 2013 21 September 2013 Denver, CO Session Objectives
More informationPart 1. What are MPTs & why do we need them?
Faculty Disclosures Multipurpose Prevention Technologies (MPTs): The Intersection of Contraceptives, HIV & STDs Dr. Young Holt has no disclosures Bethany Young Holt, PhD MPH CAMI/Public Health Institute
More informationSupporting Agency Coordination and Cooperation in the Development of Contraceptive Methods Appropriate for Provision and Use in Low Resource Settings
Supporting Agency Coordination and Cooperation in the Development of Contraceptive Methods Appropriate for Provision and Use in Low Resource Settings Judy Manning, PhD Office of Population & Reproductive
More informationReview Article Developing Multipurpose Reproductive Health Technologies: An Integrated Strategy
AIDS Research and Treatment Volume 2013, Article ID 790154, 15 pages http://dx.doi.org/10.1155/2013/790154 Review Article Developing Multipurpose Reproductive Health Technologies: An Integrated Strategy
More informationSTI vaccines are a major priority for sustainable global STI control. Large number of infections globally
Brisbane, 4 Sept 05 STI are a major priority for sustainable global STI control Preliminary WHO estimates: 357 million new cases of curable STIs in 0 The global roadmap for STI : Moving forward Large number
More informationTable for Identifying Knowledge Gaps for Use in the World Report on Knowledge for Better Health
Table for Identifying Knowledge Gaps for Use in the World Report on Knowledge for Better Health Types of knowledge needed Maternal and Newborn Health Family Planning Unsafe abortion RTI/STIs New knowledge
More informationToward global prevention of sexually transmitted infections: the need for STI vaccines
Training Course in Sexual and Reproductive Health Research 2017 Module: Sexually transmitted infections, HIV/AIDS Toward global prevention of sexually transmitted infections: the need for STI vaccines
More informationWhy Condoms Still Matter. Bidia Deperthes Sr HIV Prevention Advisor- AIDS 2018 Amsterdam
Why Condoms Still Matter Bidia Deperthes Sr HIV Prevention Advisor- UNFPA @ AIDS 2018 Amsterdam 1 Condoms: Multipurpose Devices Male and female condoms are the only barrier methods that simultaneously
More informationMultipurpose prevention technologies (MPTs): a promising response to current challenges around hormonal contraceptive methods and HIV
Multipurpose prevention technologies (MPTs): a promising response to current challenges around hormonal contraceptive methods and HIV 27 January 2016 10:30-11:50 AM Kintamani 1 2016 International Conference
More informationMTN 2011 Annual Meeting Arlington, VA. The Microbicide Pipeline: A Critical Review. J. Romano March 29, 2011
MTN 2011 Annual Meeting Arlington, VA The Microbicide Pipeline: A Critical Review J. Romano March 29, 2011 What is the microbicide pipeline and how is it prioritized and progressed? The Microbicide Pipeline?
More informationtransmission (MTCT) of
Training Course in Sexual and Reproductive Health Research 2013 Module: Principles and Practice of Sexually Transmitted Infections Prevention and Care Dual elimination of mother-to-child transmission (MTCT)
More informationFactors Affecting Dose Selection
Long Acting Injectables for HIV-PrEP Factors Affecting Dose Selection June 14 to 16, 2017 Mark Milad Milad Pharmaceutical Consulting, LLC Consultant to the Bill and Melinda Gates Foundation Outline Challenges
More informationRon Gray, MBBS, MFCM, MSc Johns Hopkins University. STIs in an International Setting
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationPresentation Overview
Effectiveness of female condoms in the prevention of pregnancy and sexually transmitted infections Bidia Deperthes Technical Advisor Condom Programming United Nations Population Fund Theresa Hatzell Hoke
More informationPre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:
Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationContraception for Women and Couples with HIV. Knowledge Test
Contraception for Women and Couples with HIV Knowledge Test Instructions: For each question below, check/tick all responses that apply. 1. Which statements accurately describe the impact of HIV/AIDS in
More informationInternational Partnership for Microbicides
International Partnership for Microbicides New Directions in Microbicide Research Accelerating an HIV Prevention Revolution: A Roadmap Zeda F. Rosenberg, ScD, Chief Executive Officer Washington, DC, March
More informationHormonal contraception and HIV risk
Hormonal contraception and HIV risk Jared Baeten, MD, PhD Departments of Global Health, Medicine, and Epidemiology, University of Washington On behalf of the ECHO Consortium HPTN Annual Meeting Washington
More informationHIV-1 and STDs in a rapidly transforming China challenges to disease prevention
HIV-1 and STDs in a rapidly transforming China challenges to disease prevention A l l e n Z. W u N a n j i n g U n i v e r s i t y E x p l o r i n g C o m m o n a l i t i e s i n G l o b a l H e a l t
More informationMTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012
MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled
More informationThe contents are the responsibility of CAMI/Public Health Institute and do not necessarily reflect the
The Wellcome Trust, which hosted this Forum, is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health through supporting the brightest minds in biomedical
More informationDeveloping a Target Product Profile for a Preventive HIV Vaccine
Developing a Target Product Profile for a Preventive HIV Vaccine Topics to be Covered Overview of TPPs What are they? What is the purpose and benefit of using a TPP? What is usually in a TPP? What are
More informationInitiative for Multipurpose Prevention Technologies (IMPT) mission IMPT
The Initiative for Multipurpose Prevention Technologies (IMPT) for sexual and reproductive health was established in the spring of 2009 to unite reproductive health researchers, health care providers,
More informationPopulation attributable fraction of genital inflammation and ulceration in HIV risk among discordant couples, Zambia,
Population attributable fraction of genital inflammation and ulceration in HIV risk among discordant couples, Zambia, 1994-2012 10 th International Workshop on HIV Transmission Kristin M. Wall, PhD kmwall@emory.edu
More informationWelcome and State of the Network. Cape Town, South Africa 27 th September 2016
Welcome and State of the Network Cape Town, South Africa 27 th September 2016 The HIV/AIDS Epidemic in 2016 17 million people were accessing antiretroviral therapy 36.7 million people globally were living
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Advancing HIV Prevention Options for Women GNP+ Consultation on NPTs Thomas Mertenskoetter 5. 6. July 2010, Amsterdam Leading Causes of Death in Women (Age 15
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Female-Initiated Prevention: State of the Art Dr. Zeda F. Rosenberg German-Austrian AIDS Congress Frankfurt, Germany 29 June 2007 Women s Vulnerability to HIV
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationHIV Prevention for People Living with HIV/AIDS: Indicators for HIV Care and Treatment Settings
HIV Prevention for People Living with HIV/AIDS: Indicators for HIV Care and Treatment Settings Daniel Kidder, PhD Pam Bachanas, PhD Amy Medley, PhD HEATLHQUAL All Country Learning Network (ACLN) Meeting
More information9p1 Identify the factors that contribute to positive relationships with others. 9p6 Describe the factors that lead to responsible sexual relationships
Lesson Eight Title: Theme: Time: Materials: Wrapping up the Sexual Health Unit The 60 minutes * Sexuality Review-Quiz * Sexuality Review-Answer Sheet * Sexual Q & A -Laminated Game Cards * Sexual Q & A
More informationDiflucan oral. Cari untuk: Cari Cari
Cari untuk: Cari Cari Diflucan oral Diflucan (fluconazole) is used to treat and prevent fungal infections. Includes Diflucan side effects, interactions and indications. 1-3-2018 Diflucan Dosage. Generic
More information1.Abstinence no sex (Abstinence only education has been proven ineffective in preventing unwanted pregnancies)
REPRODUCTIVE SYSTEM Objectives: 1. Contraception 2. STDs 1. Ovary Transplants 2. Freezing Eggs 3. Choosing Gender 4. The Male Pill, parts 1&2 5. Male Birth Control: RISUG 6. Birth Control. 1.Abstinence
More informationOutline. HIV and Other Sexually Transmitted Infections. Gonorrhea Epidemiology. Epidemiology 11/2/2012
HIV and Other Sexually Transmitted Infections Tanya Kowalczyk Mullins, MD, MS Division of Adolescent Medicine Cincinnati Children s Hospital Medical Center Outline Epidemiology of select STIs and HIV STIs
More informationLooking at NY: Our rate of chlamydia is higher than the US as a whole; we rank 13th among all states.
1 In this presentation, we will discuss: What are the most common STDs in NYS What are the most common STDs Can I get gonorrhea from oral sex How do you know if you/or your partner has an STD? Does getting
More informationSexually Transmitted Infection Treatment and HIV Prevention
Sexually Transmitted Infection Treatment and HIV Prevention Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine STI Treatment and HIV Prevention.
More informationPopulation Council Strategic Priorities Framework
Population Council Strategic Priorities Framework For 65 years, the Population Council has conducted research and delivered solutions that address critical health and development issues and improve lives
More informationSexual and Reproductive Health and HIV. Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012
Sexual and Reproductive Health and HIV Dr. Rita Kabra Training course in Sexual and Reproductive Health Research Geneva 2012 Global estimates of HIV-(2009) People living with HIV 33.3 million [31.4 35.3
More informationN A S D A Q : E V F M
N A S D A Q : E V F M Jefferies Global Healthcare Conference June 7, 2018 Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More informationAFR/RC67/7 13 June 2017
13 June 2017 REGIONAL COMMITTEE FOR AFRICA Sixty-seventh session Victoria Falls, Republic of Zimbabwe, 28 August 1 September 2017 ORIGINAL: ENGLISH Provisional agenda item 10 GLOBAL HEALTH SECTOR STRATEGY
More informationSTI Prevention: Housekeeping and How We Use Public Health. M. Terry Hogan, MPH Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationGlobal Forum on MTP for Reproductive Health: Involving end users and providers. MBATIA Redempta ICAP, Columbia University 11 th -12 th Jan 2012
Global Forum on MTP for Reproductive Health: Involving end users and providers MBATIA Redempta ICAP, Columbia University 11 th -12 th Jan 2012 Background Rationale for having Multiple Prevention Technologies
More informationSexually Transmitted Infections in HSV-2 Seropositive women in Sub- Saharan Africa HPTN 039
Sexually Transmitted Infections in HSV-2 Seropositive women in Sub- Saharan Africa HPTN 039 Ulrika Makuraj, MBBCH University of Witwatersrand Mentor : Sinead Delany-Moretlwe South Africa 17 May 2018 Introduction
More informationSCREENING AND ENROLLMENT CONSIDERATIONS MTN-038 STUDY-SPECIFIC TRAINING
SCREENING AND ENROLLMENT CONSIDERATIONS MTN-038 STUDY-SPECIFIC TRAINING SCREENING AND ENROLLMENT VISITS Screening/ Visit 1 Eligibility Criteria initially assessed Multiple visits, if needed (Split visit)
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationAcidform Vaginal Gel Contraception and STI Prevention
Acidform Vaginal Gel Contraception and STI Prevention Empower Women. Change the World. David R. Friend, PhD Sr VP, R & D 1 Acidform Gel Acidform is a viscous, acidic (ph 3.5) gel with a high buffering
More informationRSV vaccine research and development: WHO technical roadmap
RSV vaccine research and development: WHO technical roadmap Johan Vekemans (MD, PhD) WHO Initiative for Vaccine Research Washington, 18 th December 2017 What is WHO s Initiative for Vaccine Research (IVR)
More informationWhat do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women
What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women 6 August 2014, Lilongwe Question #1 HIV testing and safety
More informationInnovation, Access and Use Department of Essential Medicines and Health Products WHO
MARKETS FOR QUALITY-ASSURED PRODUCTS Sarah Garner and Francisco Blanco Innovation, Access and Use Department of Essential Medicines and Health Products WHO 1 Objectives Indicate market needs for medicines
More informationPROGRESS REPORT OF THE IMPLEMENTATION OF THE GLOBAL STRATEGY FOR PREVENTION AND CONTROL OF SEXUALLY TRANSMITTED INFECTIONS:
PROGRESS REPORT OF THE IMPLEMENTATION OF THE GLOBAL STRATEGY FOR PREVENTION AND CONTROL OF SEXUALLY TRANSMITTED INFECTIONS: 2006 2015 Document for the World Health Assembly 27 April 2015 ii Contents Acronyms
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Sharon Hillier, Ph.D. University of Pittsburgh Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine
More informationSocio-behavioral perspectives and MPT product profiles: the HPV vaccine experience
Socio-behavioral perspectives and MPT product profiles: the HPV vaccine experience Vivien Tsu, PhD, MPH Multipurpose Prevention Technologies for Reproductive Health, 2011 Symposium Washington DC, November
More informationAn Update on FACTS 001. Prof Helen Rees FACTS Protocol Chair
An Update on FACTS 001 Prof Helen Rees FACTS Protocol Chair FACTS 001 A Phase III, Multi-Centre, Randomised Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir
More informationA Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)
A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP) Delivette Castor, PhD USAID Jason Reed, MD, MPH Jhpiego Timothy Mah, DSc USAID Global Health Mini-University September 14, 2017 Presentation
More informationUnderstanding contraceptive choices among a cohort of HIV-positive women
Understanding contraceptive choices among a cohort of HIV-positive women Malika Sharma, MD FRCPC with Blitz S, Walmsley S, Raboud J, Money D for the CTN 236 investigators January 13, 2014 Conflict of Interest
More informationLTASEX.INFO STI SUMMARY SHEETS FOR EDUCATIONAL USE ONLY. COMMERCIAL USE RIGHTS RESERVED. COPYRIGHT 2013, JEROME STUART NICHOLS
LTASEX.INFO STI SUMMARY SHEETS FOR EDUCATIONAL USE ONLY. COMMERCIAL USE RIGHTS RESERVED. COPYRIGHT 2013, JEROME STUART NICHOLS LTASEX.INFO! IN AIDS is a treatable complication of advanced HIV infection.
More informationII. Adolescent Fertility III. Sexual and Reproductive Health Service Integration
Recommendations for Sexual and Reproductive Health and Rights Indicators for the Post-2015 Sustainable Development Goals Guttmacher Institute June 2015 As part of the post-2015 process to develop recommendations
More informationUpdate on PrEP progress: WHO/UNAIDS challenges and actions
Update on PrEP progress: WHO/UNAIDS challenges and actions Kevin R. O'Reilly Prevention in the Health Sector, HIV/AIDS Department, WHO HQ Outline Review current status of PrEP Planning for PrEP Pre-exposure
More informationPercentage of family planning clinics, according to clinic characteristics, by service focus, Title X funding status and clinic type, 2010 and 2015
TABLE 1 Percentage of family planning, according to clinic characteristics, by service focus, Title X funding status and clinic type, 2010 and Clinic characteristics 2010 Yes No Focuses on reproductive
More informationHormonal contraceptive methods & HIV acquisition in women: updated systematic review of epidemiological evidence
Hormonal contraceptive methods & HIV acquisition in women: updated systematic review of epidemiological evidence CHELSEA B. POLIS, PHD SEPTEMBER 16, 2016 AVAC WEBINAR GUTTMACHER INSTITUTE 2016 Acknowledgements
More informationPrEP in young African women: Rationale & lessons from HPTN 082 (and other studiesp
PrEP in young African women: Rationale & lessons from HPTN 082 (and other studiesp Connie Celum MD MPH Departments of Global Health and Medicine University of Washington Disproportionate Success in Epidemic
More informationHIV Prevention. Recent Advances and Implications for the Caribbean
HIV Prevention Recent Advances and Implications for the Caribbean Chris Behrens, MD CCAS/CHART Conference Barbados, August 2010 Cases 200 180 160 140 120 100 80 60 40 20 0 Year HIV Cases AIDS Cases HIV
More informationContraception for Adolescents: What s New?
Contraception for Adolescents: What s New? US Medical Eligibility Criteria for Contraceptive Use Kathryn M. Curtis, PhD Division of Reproductive Health, CDC Expanding Our Experience and Expertise: Implementing
More informationThe HIV Prevention Product Pipeline for Adolescents JANUARY 8 TH, 2018
The HIV Prevention Product Pipeline for Adolescents SYBIL HOSEK, PHD DEPARTMENT OF PSYCHIATRY, STROGER HOSPITAL OF COOK COUNTY I NTER-CFAR ARV FOR PREVENTION WORKING GROUP WEBINAR JANUARY 8 TH, 2018 Conflicts
More informationProduct Development for Vaccines Advisory Committee:
Product Development for Vaccines Advisory Committee: Highlights from the 2016 year of vaccine development SAGE, October 2016 David C. Kaslow, MD Chair, Product Development for Vaccines Advisory Committee
More informationMTN-038 Clinical Considerations. Site Specific Training 11 Sept 2018
MTN-038 Clinical Considerations Site Specific Training 11 Sept 2018 Overview Medical and Menstrual History Physical and Pelvic Exams STI/RTI/UTIs Con Meds Contraception Prohibited Meds and Practices Product
More informationWhat We Will Learn From the REACH Study
What We Will Learn From the REACH Study Lulu Nair (MBChB, MPH) MTN 034/IPM 045 Protocol Chair On behalf of protocol team 19 Sep 2017 MTN Regional Meeting 2017 Cape Town Overview Importance / Value of REACH
More informationAddressing the Gaps Between Products and People at Risk
Addressing the Gaps Between Products and People at Risk Albert Liu, MD, MPH Clinical Research Director, Bridge HIV SF Department of Public Health Assistant Clinical Professor of Medicine, UCSF MTN Annual
More information2
1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive
More informationThe Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial A Multi-Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone
More informationARVs for prevention in at-risk populations: Microbicides
ARVs for prevention in at-risk populations: Microbicides Treatment as Prevention in Africa Meeting Botswana, April 30 May 3, 2014 Salim S Abdool Karim Director: CAPRISA Pro Vice-Chancellor (Research):
More informationTrichomoniasis allergic flagyl
Trichomoniasis allergic flagyl The Borg System is 100 % Trichomoniasis allergic flagyl Dec 1, 2004. Because metronidazole is the only agent that is used to treat T. vaginalis infection, potential management
More informationTRANS-NIH PLAN FOR HIV RELATED RESEARCH
National Institutes of Health FY 2018 TRANS-NIH PLAN FOR HIV RELATED RESEARCH Prepared by the Office of AIDS Research Maureen M. Goodenow, Ph.D. NIH Associate Director for AIDS Research and Director, Office
More informationTasP - Individual versus Public Health Benefit versus Both.
Site Map l Contact Us l Calendar l Join AVAC Donate TasP - Individual versus Public Health Benefit versus Both. Kevin Fisher Policy Director, AVAC June 2012 Multiple choice answer: all of the above We
More informationWhy do we need male contraceptive methods?
Why do we need male contraceptive methods? Kirsten M Vogelsong UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) World Health Organization
More informationKenya. Service Provision Assessment Survey Family Planning Key Findings
Kenya Service Provision Assessment Survey 2004 Family Planning Key Findings This report summarizes the family planning findings of the 2004 Kenya Service Provision Assessment Survey (KSPA), carried out
More informationThe Role of Individual and Relationship Factors on Contraceptive Use among At-Risk Young Adults
The Role of Individual and Relationship Factors on Contraceptive Use among At-Risk Young Adults Lisa Oakley, PhD MPH 1 Marie Harvey, DrPH MPH 1 Isaac Washburn, PhD 2 April 1, 2016 Society of Behavioral
More informationWHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES
WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES SURVEY QUESTIONNAIRE A.1. Introduction The Global Action Plan for Influenza Vaccines (GAP) was launched in 2006 as a ten year initiative to address the anticipated
More informationThe case for Multipurpose Prevention Technologies
The case for Multipurpose Prevention Technologies Professor Helen Rees Executive Director, WRHI, Wits Reproductive Health and HIV Institute Ad Hominem Professor, Department of Obstetrics and Gynaecology,
More informationConsultation on the Draft National Strategies for Blood Borne Viruses and Sexually Transmissible Infections
Consultation on the Draft National Strategies for Blood Borne Viruses and Sexually Transmissible Infections AFAO comments on draft Third National Sexually Transmissible Infections Strategy 2014 2017 AFAO
More informationMTN-020 and IPM 027 and the MTN-020 DSMB. Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012
MTN-020 and IPM 027 and the MTN-020 DSMB Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012 Developing a range of options for antiretroviral-based HIV prevention Pill
More informationAdherence-enhancing intervention in PrEP in low-resource settings
Adherence-enhancing intervention in PrEP in low-resource settings Collaboration project: Bill and Melinda Gates Foundation project team Terrence F. Blaschke, Papa Salif Sow Kenya project team, LVCT Health
More informationAction Item for 2019 Review of Tool. Maintain (add include oral cavity) Maintain. Archive. Archive. 12 creatinine)
NEWLY DIAGNOSED/ NEW TO CARE PROGRAM SITE: REVIEWER(S): REVIEW DATE: CORE SERVICES Outpatient/Ambulatory Health Services Tool - 2018 (OLD) SECTION 1: CHART REVIEW Review for newly diagnosed HIV patients
More informationSummary of Expected Insights from Oral PrEP Projects in Kenya. LVCT Health in partnership with FSG and AVAC
June 2017 Summary of Expected Insights from Oral PrEP Projects in Kenya LVCT Health in partnership with FSG and AVAC Introduction A number of questions remain around how best to provide PrEP for target
More informationThe Impact of Sexually Transmitted Diseases(STD) on Women
The Impact of Sexually Transmitted Diseases(STD) on Women GAL Community Symposium AUM September 2, 2011 Agnes Oberkor, MPH, MSN, CRNP, Nurse Practitioner Senior Alabama Department of Public Health STD
More informationSEX AND SEXUALLY TRANSMITTED INFECTIONS
SEX AND SEXUALLY TRANSMITTED INFECTIONS Sex and STIs Be fully informed, Be safe! Prevent Pregnancy Practice abstinence Use effective birth control Use Emergency Contraception Prevent STI s Practice Abstinence
More informationUnderstanding the results of CAPRISA 004
A Cascade of Hope and Questions Volume 2 Understanding the results of CAPRISA 004 Key messages CAPRISA 004 provides the first proof of concept that a microbicide (1% tenofovir gel) can reduce women s risk
More informationHormonal Contraceptives and HIV Risk: HPTN 035
Hormonal Contraceptives and HIV Risk: HPTN 035 Z. Mike Chirenje MD FRCOG UZ-UCSF Collaborative Research Program Harare, Zimbabwe chirenje@uz-ucsf.co.zw Washington DC 20 Feb 2012 Outline of Presentation
More informationSTI and BV prevalence in young women in Cape Town and Soweto
STI and BV prevalence in young women in Cape Town and Soweto Shaun Barnabas Genital Mucosal and STI lab Desmond Tutu HIV Foundation University of Cape Town FAMCRU University of Stellenbosch WISH: Women
More informationWHO INFLUENZA VACCINE RECOMMENDATION
WHO INFLUENZA VACCINE RECOMMENDATION Strategic Advisory Group of Experts (SAGE) on Immunization SAGE Working Group on Influenza Vaccine and Immunization 1 Evidence Evaluation: Conceptual Matrix Target
More informationWhat s in the Biomedical Prevention Pipeline
What s in the Biomedical Prevention Pipeline HIV Endgame: Closing Gaps in the Care Cascade Toronto, 24 th October 2016 Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA Presenter Disclosure
More informationDeveloping New Signal Functions to Assess the Capacity of Health Facilities to Clinically Manage Sexual Violence Survivors in Central Province, Zambia
Developing New Signal Functions to Assess the Capacity of Health Facilities to Clinically Manage Sexual Violence Survivors in Central Province, Zambia 1 M. Dennis, 2 N. Chelwa, 1 M. Colombini, 3 O. Owolabi,
More informationJennifer Zeng. Chapel Hill. Summer Daniel Jonas. 7/10/18 Date. Leila Kahwati. 6/29/2018 Date
Effect of Long Acting Reversible Contraceptives on Dual Method Use and Incidence of Sexually Transmitted Infections among Female Adolescents and Young Adults in the United States: A Systematic Review By
More informationPractice Steps for Implementation of Guidelines Recommendations The guideline recommendations are shown schematically -
ASK SCREEN Test for HIV and STI Practice Steps for Implementation of Guidelines Recommendations The guideline recommendations are shown schematically - Routinely obtain a thorough sexual history from all
More informationSexually Transmitted Infections in Vulnerable Groups. Kevin Rebe
Sexually Transmitted Infections in Vulnerable Groups Kevin Rebe Definition: Key Populations Key populations are: Defined groups who, due to specific higher-risk behaviours, are at increased Men risk who
More information